BridgeBio Pharma BBIO 深 滬
等待開盤 09-30 09:30:00 美东时间
51.96
+1.910
+3.82%
華盛通- 最 高52.45
- 今 開50.68
- 成交量 195.48万股
- 最 低 50.50
- 昨 收 50.05
- 總市值 99.24亿
- 52周最高 54.60
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 21.72
- 委 比 -90.20%
- 總股本 1.91亿
- 歷史最高 73.50
- 量 比 0.95
- 振 幅 3.90%
- 歷史最低 4.98
- 每 手 1
- 風險率 8.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Can Disney Keep Growth Momentum Despite Cruise Delays And Travel Worries?
Walt Disney Co. (NYSE: DIS) is poised for a stronger-than-expected fourth quarter as a combination of rising theme park attendance, per-capita spending, and strategic pricing moves across its parks and streaming services positions the company to outperform revenue and profit expectations.
今天 01:04
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
Acoramidis demonstrated early and sustained clinical efficacy in reducing cumulative cardiovascular outcomes in ATTR-CM patients. By Month 1, fewer cumulative events were observed versus placebo, with a 49% hazard reduction at Month 30 (p<0.0001). At Month 30, 53 events were avoided per 100 treated participants (95% CI:29–79). Continuous treatment through Month 42 reduced CVM by 45% (p=0.0011). These findings highlight the importance of early tre...
09-28 15:15
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
BridgeBio Pharma announced that it will present four clinical trial findings at the HFSA 2025 meeting: one late-breaking trial, one oral presentation, and three posters. These sessions focus on Acoramidis' effects in ATTR-CM patients, including reductions in cardiovascular outcomes and mortality. The company highlighted safety data showing mild adverse events like diarrhea and upper abdominal pain. BridgeBio emphasizes its commitment to genetic d...
09-22 11:30
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
美股异动|辉瑞股价大跌创低位 市场竞争与政策不确定性拖累表现
（来源：美股情报站） 9月12日，辉瑞公司股价下跌3.98%，创下2025年8月以来的新低。这样的市场表现无疑引发了投资者的关注和疑问。最近，辉瑞在与bri...
09-13 06:31
CDC to offer contract to study link between vaccines and autism
The U.S. Centers for Disease Control and Prevention (CDC) proposes to offer a contract opportunity to Rensselaer Polytechnic Institute to run a study on a potential link between vaccination and autism...
09-13 00:19
UBS Maintains Buy on BridgeBio Pharma, Raises Price Target to $82
UBS analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $72 to $82.
09-12 22:26
BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争
BridgeBio Pharma称其一款心脏病药物疗效更优且成本更低，但同时指控竞争对手在这个价值数十亿美元的市场中采用“有争议的策略”进行竞争。
09-12 08:27
Cuba hit by nationwide blackout as grid collapses again
Cuba’s fragile power grid suffered its fourth nationwide collapse in less than a year on Wednesday, leaving the island’s 10 million residents without electricity. Officials said the system went down j...
09-11 00:36
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma announced equity grants in the form of restricted stock units (RSUs) to new employees under its 2019 Inducement Equity Plan. The compensation committee approved RSU grants totaling 33,684, 32,145, and 73,991 shares on September 5, August 4, and July 14, 2025, respectively. A quarter of the shares vest on August 16, 2026, with the remainder vesting quarterly over three years, contingent on continued employment. Additionally, 98,34...
09-10 20:01
